PharmaTelevision - Kymab: Tom Shepherd explains why the 'Kymouse' is an excellent way of producing high quality antibodies

PharmaTelevision requires Javascript enabled and Adobe Flash Player to watch our programmes. If you do not have Flash installed, you can download it for free from the Adobe Flash homepage.

Improve your Internet experience and start watching exciting new video content.

Video title: Kymab: Tom Shepherd explains why the 'Kymouse' is an excellent way of producing high quality antibodies

Visitors: You are watching a 5 minute preview.

Get more information and subscribe now

RSS

Twitter

In This Episode:

Summary
Transcript
Participants
Company

In this episode of PharmaTelevision News Review, Fintan Walton talks to Tom Shepherd, CBO of Kymab.

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Kymab's Kymouse platform and technology

Fintan Walton:

Hello and welcome to PharmaTelevision News Review here at BIO-Europe, in Duesseldorf 2011. On this show I have Tom Shepherd, who is Chief Business Officer at a company called Kymab based in Cambridge in the UK, welcome.

Tom Shepherd:

Thanks a lot, thanks for having me on this show.

Fintan Walton:

Pleasure. Tom, can you tell us a little bit about Kymab?

Tom Shepherd:

Kymab is a recent spin-out from the Sanger Institute in Cambridge based around the combination of the ES cell technologies of the institute, Professor Allan Bradley was the founder coupled with the antibody and immunology skills of Mike Owen who is the Chief Scientific Officer.

Fintan Walton:

Okay, so obviously when you enter into the area of antibodies you have to bring something new to the table, so what is new? What is different? What's unique about Kymab?

Full video transcripts are available with PharmaTelevision Premium Content. Click here to buy a subscription or sign up for a 14 day free trial.

Fintan Walton

Dr Fintan Walton is the Founder and CEO of PharmaVentures . After completing his doctoral research on the genetics of cell proliferation at the University of Michigan(US)and Trinity College (Dublin, Ireland), Dr Walton gained broad commercial experience in biotechnology in management positions at Bass and Celltech plc (1982-1992).

Tom Shepherd

Chief Business Officer

At the time of recording this PTV interview Tom Shepherd Chief Business Officer of Kymab. Dr. Shepherd has over 30 years experience in the pharmaceutical industry including CEO and executive business development roles in the USA, Europe and Australia. He has led multiple pharmaceutical asset and technology licensing transactions and has been responsible for strategic company-building acquisitions. He has also raised significant amounts of equity capital to build early stage companies in to sustainable commercial operations. Dr. Shepherd was previously CEO of CXR Biosciences and Neurotech S.A and Vice President Business Development at ICN Pharmaceuticals and Intrabiotics Pharmaceuticals. Dr. Shepherd was awarded a Ph.D. in biochemistry from the University of Strathclyde in 1981 and completed the CEP programme at the London Business School in 1989.

PharmaVentures

PharmaVentures is a corporate finance and transactions advisory firm that has served hundreds of clients worldwide in relation to their strategic deal making in the pharmaceutical, life science and healthcare sectors. Our key offerings include: Transactions / deal negotiations; Product / technology valuations; Deal term advice; Due diligence & expert reports; Strategy formulation; Alliance management; and Expert opinion for litigation/arbitration cases. PharmaVentures provides the global expertise to ensure our clients generate the highest possible return on investment from all their deal making activities. We have experience of all therapeutic areas and can offer advice on both product and technology commercialisation.

Kymab

Kymab was founded in 2009 to develop a mouse-based human antibody discovery platform, the Kymouse, designed to have a superior repertoire of B-cell mediated immune responses to current in vivo systems. Kymab will use the Kymouse platform to discover and develop potent and selective therapeutic antibodies for development as biopharmaceuticals. The company raised "20m of equity financing from the investment division of the Wellcome Trust. The creation of the Kymouse platform relies on cutting edge molecular biology and sophisticated mouse ES cell manipulation that few groups in the world can perform. Kymab has benefited from the leading embryonic stem cell technology developed in the laboratory of Professor Allan Bradley, Emeritus Director of the Wellcome Trust Sanger Institute, Cambridge UK and co-founder of Lexicon Genetics. As a "platform to product" biopharmaceutical company Kymab's strategy is to use proprietary Kymouse transgenic antibody platform for the in-house development of a product portfolio and to partner with others to maximize its application in the development of novel therapeutics.